Clinical Trial

AZA Combined With RCHOP in P53-mutated DLBCL.

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 19, 2025 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and adverse effects of Azacitidine in combination with R-CHOP (ARCHOP) for the treatment of TP53-mutated previously untreated Diffuse large B-cell lymphoma
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-11-28; most recent amendment 2025-02-18.
Trial Details
NCT Number NCT06158399
Lead Sponsor The First Affiliated Hospital of Xiamen University
Collaborators: Jiangsu Provincial People's Hospital, Sun Yat-sen University, Chinese Academy of Medical Sciences, Shanxi Province Cancer Hospital
Conditions DLBCL - Diffuse Large B Cell Lymphoma, TP53
Enrollment 52 participants
Start Date 2023-11-22
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-19